Why the study?
Does rivaroxaban prevent stroke and thromboembolism in patients with non-valvular atrial fibrillation in everyday clinical practice?
Does rivaroxaban prevent stroke and thromboembolism in patients with non-valvular atrial fibrillation in everyday clinical practice?
Real-world clinical cases support the efficacy and safety of rivaroxaban for stroke prevention in non-valvular atrial fibrillation, consistent with pivotal trial data.
Real-world rivaroxaban use in non-valvular AF matches ROCKET-AF expectations; supports but leaves open confirmation in larger prospective studies.
The article tells about the experience with rivaroxaban for the prevention of stroke and thromboembolism not involving the central nervous system vessels in patients with non-valvular atrial fibrillation in a number of clinical cases. The article demonstrates that rivaroxaban’s efficacy and safety in everyday medical practice, in general, meets the expectations resulting from the large controlled ROCKET-AF trial.
No takes yet. Share an insight, caveat, or question.
I. S. Yavelov (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: